As Pfizer (PFE - Get Report) struck a deal that gives it a therapy serving atopic dermatitis on Monday, shares of another biotech company betting on a similar treatment rallied.  

Regeneron Pharmaceuticals (REGN - Get Report) added about 6%, or $22.50 per share, to close at $391.95 Monday afternoon.

Pfizer said Monday morning it plans to spend $5.2 billion to acquire Anacor Pharmaceuticals (ANAC , through which it will gain access to Crisaborole, an anti-inflammatory drug currently under U.S. Food and Drug Administration review for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.

The deal comes as Regeneron, a Tarrytown, N.Y.-based biotech company, works toward the expected launch of its eczema drug Dupilumab next year in collaboration with Sanofi (SNY - Get Report) .

But according to Jefferies analyst Biren Aimin, the stock's movement on Monday has more to do with a Saturday article by Barron's, which made a case that Regeneron is positioned as "the best bet in biotech stocks". The report argues that shares of Regeneron could grow 35% in a year. 

Company followers agree that Regeneron, a nearly $40.1 billion market cap company as of Monday, sits in a strong position from a pipeline perspective. 

While the focus has been almost elusively on Regeneron's eye therapy Eylea, investor eyes are beginning to shift to what remains a very rich pipeline, noted Brean Capital analyst Jason Wittes.   

"The good news is that even if Eylea gets long in the tooth, even if growth slows down, these [pipeline drugs] will pick up the slack," Wittes said. "Dupilumab is the most interesting."  

Dupilumab, a treatment for moderate-to-severe atopic dermatosis in adults, is expected to launch in the mid-2017. Meanwhile, the FDA is expected to make its approval decision on Pfizer's Crisaborole by Jan. 7, 2017. 

Pfizer is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells PFE? Learn more now.

"It's an interesting new market opportunity that hasn't been tapped by pharma companies," Wittes said, referring to the eczema market. "These patients are highly symptomatic so they're not going to wait around."

Eylea will likely continue to grow steadily, and at least one additional trial for the company this year could potentially expand the patient population even further, he said. 

Also in the pipeline for Regeneron is rheumatoid arthritis therapy Sarilumab, but Wittes said he holds a modest view on it because this class of drugs continues to face safety concerns and is in a market facing greater competition.
 
Besides its best-selling product Eylea, Regnereon's current portfolio of marketed drugs includes Praulent, a treatment for adults with high cholesterol. The future for the latter remains uncertain. 
 
While Praulent has been "treading water" amid competition from a similar Amgen ( AMGN - Get Report) treatment, an upcoming study known as the Odessy Outcomes may support the value of the drug and serve as an additional catalyst, Wittes said: "It looks like an interesting drug, but until data is out really proving the drug, there's not a rush in the marketplace." 

At the same time, investors are currently awaiting the results of a patent infringement case on the anti-cholesterol drug anticipated this summer. Amgen in March won a patent dispute in a U.S. District Court against Amgen and Praulent's development partner Sanofi, following which the latter two appealed. If the judge in its final verdict issues a permanent injunction, Regeneron will probably have to take Praulent off the market.  

"Where Praulent expectations are going into the end of the year are going to be key," Aimin said.